and the role of miR-3151 was first evaluated in SKM-1 cells.SKM-1 cells were treated with different concentrations of HHT or Bortezomib, and cell viability was analyzed with CCK-8 assay. The influence on cell proliferation, cell cycle distribution and the percentage of apoptosis cells were analyzed by flow cytometry. Calcusyn software was used to calculate combination index (CI) values. Western blot was used to analysis phosphorylation of Akt and nuclear NF-κB protein expression in SKM-1 cells. Mature miR-3151 level and p53 protein level were detected after HHT or Bortezomib treatment. The cell proliferation and p53 protein level were reassessed in SKM-1 cells infected with lentivirus to overexpress miR-3151.Simultaneous exposure to HHT an...
[[abstract]]Bortezomib, a proteasome inhibitor, has been clinically approved for the treatment of my...
A novel drug combination of a proteasome inhibitor, bortezomib, and a histone deacetylase inhibitor,...
Bortezomib is a proteasome inhibitor. It targets the ubiquitin-proteasome pathway with subsequent in...
Myelodysplastic syndromes (MDS) are clonal marrow stem-cell disorders with a high risk of progressio...
Background Myelodysplastic syndromes (MDS) are clonal marrow stem-cell disorders with a high risk of...
<p>Western blot analyses of p-Akt, Akt (A and B), p-NF-κB, NF-κB (C and D) and p53 (F) protein expre...
Abstract Background Interactions between the protein synthesis inhibitor homoharringtonine (HHT) and...
Bortezomib is an anti-tumor agent, which inhibits 26S proteasome degrading ubiquitinated proteins. ...
<p>(A) The positive rate of GFP in miR-3151 precusor group cells. (B) miR-3151 relative expression l...
The proteasome inhibitor bortezomib is an efficacious apoptotic agent in many tumor cells. This pape...
<p>(A) Annexin V/PI double-staining flow cytometry of SKM-1 cells treated with 46.20 nM HHT, 4.46 nM...
Multiple myeloma (MM) is a malignant cancer with an increasing in incidence that can be alleviated t...
PS-341 (Bortezomib) is a dipeptide boronic acid proteasome inhibitor with antitumor activity that in...
Bortezomib is a proteasome inhibitor. It targets the ubiquitin-proteasome pathway with subsequent in...
Bortezomib, a proteasome inhibitor, has been clinically approved for the treatment of myeloma and ly...
[[abstract]]Bortezomib, a proteasome inhibitor, has been clinically approved for the treatment of my...
A novel drug combination of a proteasome inhibitor, bortezomib, and a histone deacetylase inhibitor,...
Bortezomib is a proteasome inhibitor. It targets the ubiquitin-proteasome pathway with subsequent in...
Myelodysplastic syndromes (MDS) are clonal marrow stem-cell disorders with a high risk of progressio...
Background Myelodysplastic syndromes (MDS) are clonal marrow stem-cell disorders with a high risk of...
<p>Western blot analyses of p-Akt, Akt (A and B), p-NF-κB, NF-κB (C and D) and p53 (F) protein expre...
Abstract Background Interactions between the protein synthesis inhibitor homoharringtonine (HHT) and...
Bortezomib is an anti-tumor agent, which inhibits 26S proteasome degrading ubiquitinated proteins. ...
<p>(A) The positive rate of GFP in miR-3151 precusor group cells. (B) miR-3151 relative expression l...
The proteasome inhibitor bortezomib is an efficacious apoptotic agent in many tumor cells. This pape...
<p>(A) Annexin V/PI double-staining flow cytometry of SKM-1 cells treated with 46.20 nM HHT, 4.46 nM...
Multiple myeloma (MM) is a malignant cancer with an increasing in incidence that can be alleviated t...
PS-341 (Bortezomib) is a dipeptide boronic acid proteasome inhibitor with antitumor activity that in...
Bortezomib is a proteasome inhibitor. It targets the ubiquitin-proteasome pathway with subsequent in...
Bortezomib, a proteasome inhibitor, has been clinically approved for the treatment of myeloma and ly...
[[abstract]]Bortezomib, a proteasome inhibitor, has been clinically approved for the treatment of my...
A novel drug combination of a proteasome inhibitor, bortezomib, and a histone deacetylase inhibitor,...
Bortezomib is a proteasome inhibitor. It targets the ubiquitin-proteasome pathway with subsequent in...